6190 results
Cited 15 times since 2013 (1.3 per year)
source: EuropePMC
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
Volume 46, Issue 6, 4 1 2013, Pages 624-629
Results from craniocaudal carotid body tumor resection: should it be the standard surgical approach?
Paridaans MP, van der Bogt KE, Jansen JC, Nyns EC, Wolterbeek R, van Baalen JM, Hamming JF
Objectives: To evaluate results after carotid body tumor (CBT) surgery using a novel dissection technique. Methods: A retrospective analysis of all operated CBT in the last 6 years was carried out and results were compared with the current literature and our previous series, which reported another 111 cases operated on until 2005. Results: Forty-five CBTs were removed in 41 (56% hereditary cases) patients (seven Shamblin I, 22 II, and 16 III). There were no cases of permanent cranial nerve injur...
Abstract
Cited 35 times since 2013 (3 per year)
source: EuropePMC
Journal of plastic, reconstructive & aesthetic surgery : JPRAS,
Volume 66, Issue 12, 4 1 2013, Pages 1732-1740
Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group.
de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, Breur JM, Pasmans SG
Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH). However, several side effects have been reported. Atenolol, a hydrophilic selective beta-1 blocker, could be an alternative and associated with fewer side effects. Thirty consecutive patients with IH were treated with atenolol between June 2010 and May 2011. The therapeutic effect was judged by clinical assessment and quantified by using a visual analogue scale (VAS) a...
Abstract
Cited 190 times since 2013 (16.3 per year)
source: EuropePMC
European heart journal,
Volume 34, Issue 45, 2 1 2013, Pages 3491-3500
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ
Aim: Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients. Methods and results: In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome. The primary endpoint...
Abstract
Cited 10 times since 2013 (0.9 per year)
source: EuropePMC
Pacing and clinical electrophysiology : PACE,
Volume 37, Issue 1, 2 1 2013, Pages 25-34
Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.
Thijssen J, van den Akker van Marle ME, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van Erven L, Schalij MJ
Background: Although randomized trials have shown the beneficial effect on survival of an implantable cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, the purpose of this study was to assess the cost-effectiveness of primary prevention ICD implantation in the real world. Methods: Patients receiving primary prevention single-chamber or dual-chamber ICD implantation a...
Abstract
Cited 30 times since 2013 (2.6 per year)
source: EuropePMC
PloS one,
Volume 8, Issue 9, 2 1 2013, Pages e72642
Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet S, Buckley BM, Ford I
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of pravastatin, demonstrated a 19% reduction in coronary outcomes (p=0.006) after a mean of 3.2 years, with no impact on stroke outcomes or all-cause mortality. However, there was a suggestion of increased cancer risk. Our aim is to determine the long-term benefits and safety of pravastatin treatment in older people using post-trial follow-up of the PROSPER participants. Methods: 5,804 (...
Abstract
Cited 414 times since 2013 (35.5 per year)
source: EuropePMC
The New England journal of medicine,
Volume 369, Issue 15, 2 1 2013, Pages 1395-1405
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.
Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J, Gras D, Krum H, Sogaard P, Holzmeister J, EchoCRT Study Group
Background: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. Methods: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or le...
Abstract
Cited 31 times since 2013 (2.7 per year)
source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Volume 8, Issue 9, 1 1 2013, Pages 1190-1195
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW, Dingemans AM, Thunnissen E, Snijders PJ, Derks J, Heideman DA, Van Suylen R, Smit EF
Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with dismal outcome for non-small-cell lung cancer (NSCLC) patients. The role of KRAS mutation as a predictor of response to chemotherapy for patients with metastatic NSCLC is poorly understood. Methods: From a retrospective database of two university hospitals, all patients with advanced, nonsquamous NSCLC treated with first-line platinum-containing chemotherapy were selected. Mutation analysis for K...
Abstract
Cited 58 times since 2013 (5 per year)
source: EuropePMC
Intensive care medicine,
Volume 39, Issue 11, 31 5 2013, Pages 2011-2019
Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial.
de Gast-Bakker DH, de Wilde RB, Hazekamp MG, Sojak V, Zwaginga JJ, Wolterbeek R, de Jonge E, Gesink-van der Veer BJ
Objective: To investigate the safety and effects of a restrictive red blood cell (RBC) transfusion strategy in pediatric cardiac surgery patients. Design: Randomized controlled trial. Setting: Pediatric ICU in an academic tertiary care center, Leiden University Medical Center, Leiden, The Netherlands. Patients: One hundred seven patients with non-cyanotic congenital heart defects between 6 weeks and 6 years of age. One hundred three patients underwent corrective surgery on cardiopulmonary bypass...
Abstract
Cited 4 times since 2013 (0.3 per year)
source: EuropePMC
Revista espanola de cardiologia (English ed.),
Volume 66, Issue 11, 31 5 2013, Pages 912-913
Usefulness of exercise test in cardiac resynchronization therapy follow-up.
de Riva-Silva M, López Gil M, Fontenla-Cerezuela A, Salgado-Aranda R, Salguero-Bodes R, Arribas-Ynsaurriaga F
Abstract
Cited 17 times since 2013 (1.5 per year)
source: EuropePMC
Atherosclerosis,
Volume 231, Issue 1, 31 5 2013, Pages 48-53
Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis.
Willems S, Quax PH, de Borst GJ, de Vries JP, Moll FL, de Kleijn DP, Hoefer IE, Pasterkamp G
Objective: Soluble ST2 (sST2), a novel biomarker predictive for heart disease, has recently been shown associated with the progression of atherosclerotic disease in a mouse model. The present study was designed to assess sST2 plasma levels in patients scheduled for carotid endarterectomy and relate it with the occurrence of adverse cardiovascular events during follow-up. In addition, sST2 levels were associated to patient clinical data and atherosclerotic plaque characteristics. Methods and resu...
Abstract
Cited 2394 times since 2013 (205 per year)
source: EuropePMC
European heart journal,
Volume 34, Issue 38, 30 5 2013, Pages 2949-3003
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL
Abstract
Cited 1112 times since 2013 (95.2 per year)
source: EuropePMC
European heart journal,
Volume 34, Issue 39, 30 5 2013, Pages 3035-3087
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG
Abstract
Cited 11 times since 2013 (0.9 per year)
source: EuropePMC
Circulation journal : official journal of the Japanese Circulation Society,
Volume 77, Issue 11, 29 5 2013, Pages 2793-2798
Clinical features differ substantially between Caucasian and Asian populations of Marfan syndrome.
Franken R, den Hartog AW, van de Riet L, Timmermans J, Scholte AJ, van den Berg MP, de Waard V, Zwinderman AH, Groenink M, Yip JW, Mulder BJ
Background: Prevention of aortic dissection and sudden death in patients with Marfan syndrome (MFS) requires accurate diagnosis. MFS is diagnosed by the Ghent criteria, which are primarily based on clinical features of Caucasian MFS populations. We determined whether the Ghent criteria apply to Asian MFS populations. Methods and results: In this multicenter study, we included 255 adult MFS patients according to the Ghent criteria of 2010. Patients were excluded if they were neither Caucasian nor...
Abstract
Cited 6 times since 2013 (0.5 per year)
source: EuropePMC
Pediatric hematology and oncology,
Volume 31, Issue 4, 29 5 2013, Pages 318-326
Leukapheresis in childhood acute leukemias: single-center experience.
Yilmaz D, Karapinar B, Karadaş N, Duyu M, Yazici P, Ay Y, Balkan C, Aydinok Y, Kavakli K
Hyperleukocytosis in patients with leukemia is associated with early mortality, especially due to the pulmonary and neurological complications of leukostasis. The prompt use of leukapheresis may improve patients' survival in the initial treatment period. The medical records of all previously untreated acute leukemia patients were reviewed to determine whether there was hyperleukocytosis at presentation. This study summarizes a single-center experience of leukapheresis that was applied to 12...
Abstract
Cited 74 times since 2013 (6.3 per year)
source: EuropePMC
Journal of cardiovascular translational research,
Volume 6, Issue 5, 28 4 2013, Pages 816-825
Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up.
Rodrigo SF, van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, Roelofs H, Al Younis I, Dibbets-Schneider P, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE
In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related t...
Abstract
Cited 16 times since 2013 (1.4 per year)
source: EuropePMC
Clinical research in cardiology : official journal of the German Cardiac Society,
Volume 102, Issue 11, 23 4 2013, Pages 847-856
Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study.
Hoefer IE, Sels JW, Jukema JW, Bergheanu S, Biessen E, McClellan E, Daemen M, Doevendans P, de Groot P, Hillaert M, Horsman S, Ilhan M, Kuiper J, Pijls N, Redekop K, van der Spek P, Stubbs A, van de Veer E, Waltenberger J, van Zonneveld AJ, Pasterkamp G
Biomarkers for primary or secondary risk prediction of cardiovascular disease (CVD) are urgently needed to improve individual treatment and clinical trial design. The vast majority of biomarker discovery studies has concentrated on plasma/serum as an easily accessible source. Although numerous markers have been identified, their added predictive value on top of traditional risk factors has been limited, as the biological specimen does not specifically reflect expression profiles related with CVD...
Abstract
Multimedia manual of cardiothoracic surgery : MMCTS,
Volume 2013, 23 4 2013, Pages mmt009
The Bex-Nikaidoh operation for dextro-transposition of the great arteries with a ventricular septal defect and pulmonary stenosis using an 'oversized' conduit.
Chernogrivov AE, Bazylev VV, Chernogrivov IE, Kalinicheva J, Paramonova T, Nevvazhay T
We report a case of a 4-month-old infant with dextro (d)-transposition of the great arteries, ventricular septal defect (VSD) and left ventricular outflow tract obstruction previously palliated with a systemic-to-pulmonary shunt. He underwent repair by aortic root translocation with an arterial switch procedure and coronary artery reimplantation (modified Bex-Nikaidoh operation). This case demonstrates that aortic translocation results in a more normal anatomic repair compared with the Rastelli...
Abstract
Cited 111 times since 2013 (9.5 per year)
source: EuropePMC
Circulation,
Volume 128, Issue 12, 22 4 2013, Pages 1310-1324
Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease.
Sabater-Lleal M, Huang J, Chasman D, Naitza S, Dehghan A, Johnson AD, Teumer A, Reiner AP, Folkersen L, Basu S, Rudnicka AR, Trompet S, Mälarstig A, Baumert J, Bis JC, Guo X, Hottenga JJ, Shin SY, Lopez LM, Lahti J, Tanaka T, Yanek LR, Oudot-Mellakh T, Wilson JF, Navarro P, Huffman JE, Zemunik T, Redline S, Mehra R, Pulanic D, Rudan I, Wright AF, Kolcic I, Polasek O, Wild SH, Campbell H, Curb JD, Wallace R, Liu S, Eaton CB, Becker DM, Becker LC, Bandinelli S, Räikkönen K, Widen E, Palotie A, Fornage M, Green D, Gross M, Davies G, Harris SE, Liewald DC, Starr JM, Williams FM, Grant PJ, Spector TD, Strawbridge RJ, Silveira A, Sennblad B, Rivadeneira F, Uitterlinden AG, Franco OH, Hofman A, van Dongen J, Willemsen G, Boomsma DI, Yao J, Swords Jenny N, Haritunians T, McKnight B, Lumley T, Taylor KD, Rotter JI, Psaty BM, Peters A, Gieger C, Illig T, Grotevendt A, Homuth G, Völzke H, Kocher T, Goel A, Franzosi MG, Seedorf U, Clarke R, Steri M, Tarasov KV, Sanna S, Schlessinger D, Stott DJ, Sattar N, Buckley BM, Rum
Background: Estimates of the heritability of plasma fibrinogen concentration, an established predictor of cardiovascular disease, range from 34% to 50%. Genetic variants so far identified by genome-wide association studies explain only a small proportion (90 000 subjects of European ancestry, the first genome-wide association meta-analysis of fibrinogen levels in 7 studies in blacks totaling 8289 samples, and a genome-wide association study in Hispanics totaling 1366 samples. Evaluation for asso...
Abstract
Cited 2 times since 2013 (0.2 per year)
source: EuropePMC
European heart journal,
Volume 34, Issue 41, 21 3 2013, Pages 3168-3170
High coronary plaque load: a heavy burden.
de Graaf MA, Jukema JW
Abstract
Cited 74 times since 2013 (6.3 per year)
source: EuropePMC
European heart journal,
Volume 34, Issue 42, 21 3 2013, Pages 3251-3258
Stabilization of atherosclerotic plaques: an update.
Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jauhiainen S, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoglu L, ESC Working Group of Atherosclerosis and Vascular Biology
Abstract
